Beam Therapeutics
BEAM
231 hedge funds and large institutions have $5.85B invested in Beam Therapeutics in 2021 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 85 increasing their positions, 44 reducing their positions, and 34 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 44
78% more call options, than puts
Call options by funds: $72.3M | Put options by funds: $40.6M
70% more capital invested
Capital invested by funds: $3.43B → $5.85B (+$2.41B)
65% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 34
11% more funds holding
Funds holding: 209 → 231 (+22)
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
3.77% more ownership
Funds ownership: 68.91% → 72.68% (+3.8%)
Top Buyers
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$134M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$72.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.1M |
| 4 |
JP Morgan Chase
New York
|
+$13.6M |
| 5 |
Two Sigma Investments
New York
|
+$10.6M |
Top Sellers
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$38.2M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$21.5M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$18.1M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$13.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$10.8M |
BEAM Hedge Fund Activity: Q2 2021 in Review
231 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q2 2021, worth a combined $5.85B — up 70% from $3.43B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new BEAM positions and 34 closed out — a net gain of 22 holders — while 85 added to existing stakes and 44 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $134M. The largest seller was Redmile Group, cutting an estimated $38.2M.
- 231 institutional investors held Beam Therapeutics (BEAM) as of Q2 2021, up from 209 in Q1 2021.
- Funds reported $5.85B of Beam Therapeutics stock for Q2 2021, up 70% quarter-over-quarter.
- 56 funds opened new Beam Therapeutics positions in Q2 2021 and 34 closed out, a net change of +22 holders.
- The largest Beam Therapeutics buyer in Q2 2021 was ARK Investment Management, an estimated $134M added.
- The largest Beam Therapeutics seller in Q2 2021 was Redmile Group, an estimated $38.2M sold.
Based on aggregated 13F filings for Q2 2021.